Cargando…

Physical Activity as a New Tool to Evaluate the Response to Omalizumab and Mepolizumab in Severe Asthmatic Patients: A Pilot Study

Asthma is a chronic inflammatory airway disease, representing one of the most severe pathologies in developed countries. Based on a report of the World Health Organization (WHO), it affects about 300 million people worldwide. Few studies have analyzed the effects of daily life physical activity (PA)...

Descripción completa

Detalles Bibliográficos
Autores principales: Carpagnano, Giovanna Elisiana, Sessa, Francesco, Scioscia, Giulia, Lacedonia, Donato, Foschino, Maria Pia, Venuti, Maria Pia, Triggiani, Antonio Ivano, Valenzano, Anna, Resta, Onofrio, Cibelli, Giuseppe, Messina, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6992710/
https://www.ncbi.nlm.nih.gov/pubmed/32038267
http://dx.doi.org/10.3389/fphar.2019.01630
_version_ 1783492888687017984
author Carpagnano, Giovanna Elisiana
Sessa, Francesco
Scioscia, Giulia
Lacedonia, Donato
Foschino, Maria Pia
Venuti, Maria Pia
Triggiani, Antonio Ivano
Valenzano, Anna
Resta, Onofrio
Cibelli, Giuseppe
Messina, Giovanni
author_facet Carpagnano, Giovanna Elisiana
Sessa, Francesco
Scioscia, Giulia
Lacedonia, Donato
Foschino, Maria Pia
Venuti, Maria Pia
Triggiani, Antonio Ivano
Valenzano, Anna
Resta, Onofrio
Cibelli, Giuseppe
Messina, Giovanni
author_sort Carpagnano, Giovanna Elisiana
collection PubMed
description Asthma is a chronic inflammatory airway disease, representing one of the most severe pathologies in developed countries. Based on a report of the World Health Organization (WHO), it affects about 300 million people worldwide. Few studies have analyzed the effects of daily life physical activity (PA) levels in patients with asthma: moreover, little research has been carried out on PA levels in patients suffering from severe asthma (SA). This study aimed to investigate the PA levels in two groups of patients suffering from SA; in particular, this study analyzed the changes that occur in patients treated with biologic therapy (BT group) and patients who underwent traditional treatment (TT group) over 6 months. Moreover, this study represents a pilot study because, to the best of our knowledge, it is the first investigation that analyzed if the kind of biologic drug (omalizumab or mepolizumab) can produce differences in the PA levels of SA patients. Fifty SA patients were enrolled and PA parameters were monitored for 6 months. Subjects were divided into two treatment groups: TT (20 patients) and BT (30 patients), the BT group was further subdivided according to the drugs used (15, omalizumab; 15, mepolizumab). During drug treatment, all subjects improved their PA levels: indeed, considering the intragroup variation, the PA levels were significantly higher comparing the T6 levels to baseline (T0, p < 0.01). Considering the intragroup variation, it is very interesting to note that biologic therapy improved PA levels compared to the effects of traditional therapy; while at T0 there were no significant differences in the steps per day (SPD) values between the two groups (T0, p = 0.85), the differences become statistically significant at T1, T3, and T6 (T1, p = 0.019; T3, p = 3.48x10(−6); T6, p = 4.78x10(−10)). As expected, the same differences were reported analyzing the energy expenditure data. In conclusion, this pilot study reports a positive relationship between biologic drug therapy and PA patterns, even if further studies are needed.
format Online
Article
Text
id pubmed-6992710
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-69927102020-02-07 Physical Activity as a New Tool to Evaluate the Response to Omalizumab and Mepolizumab in Severe Asthmatic Patients: A Pilot Study Carpagnano, Giovanna Elisiana Sessa, Francesco Scioscia, Giulia Lacedonia, Donato Foschino, Maria Pia Venuti, Maria Pia Triggiani, Antonio Ivano Valenzano, Anna Resta, Onofrio Cibelli, Giuseppe Messina, Giovanni Front Pharmacol Pharmacology Asthma is a chronic inflammatory airway disease, representing one of the most severe pathologies in developed countries. Based on a report of the World Health Organization (WHO), it affects about 300 million people worldwide. Few studies have analyzed the effects of daily life physical activity (PA) levels in patients with asthma: moreover, little research has been carried out on PA levels in patients suffering from severe asthma (SA). This study aimed to investigate the PA levels in two groups of patients suffering from SA; in particular, this study analyzed the changes that occur in patients treated with biologic therapy (BT group) and patients who underwent traditional treatment (TT group) over 6 months. Moreover, this study represents a pilot study because, to the best of our knowledge, it is the first investigation that analyzed if the kind of biologic drug (omalizumab or mepolizumab) can produce differences in the PA levels of SA patients. Fifty SA patients were enrolled and PA parameters were monitored for 6 months. Subjects were divided into two treatment groups: TT (20 patients) and BT (30 patients), the BT group was further subdivided according to the drugs used (15, omalizumab; 15, mepolizumab). During drug treatment, all subjects improved their PA levels: indeed, considering the intragroup variation, the PA levels were significantly higher comparing the T6 levels to baseline (T0, p < 0.01). Considering the intragroup variation, it is very interesting to note that biologic therapy improved PA levels compared to the effects of traditional therapy; while at T0 there were no significant differences in the steps per day (SPD) values between the two groups (T0, p = 0.85), the differences become statistically significant at T1, T3, and T6 (T1, p = 0.019; T3, p = 3.48x10(−6); T6, p = 4.78x10(−10)). As expected, the same differences were reported analyzing the energy expenditure data. In conclusion, this pilot study reports a positive relationship between biologic drug therapy and PA patterns, even if further studies are needed. Frontiers Media S.A. 2020-01-24 /pmc/articles/PMC6992710/ /pubmed/32038267 http://dx.doi.org/10.3389/fphar.2019.01630 Text en Copyright © 2020 Carpagnano, Sessa, Scioscia, Lacedonia, Foschino, Venuti, Triggiani, Valenzano, Resta, Cibelli and Messina http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Carpagnano, Giovanna Elisiana
Sessa, Francesco
Scioscia, Giulia
Lacedonia, Donato
Foschino, Maria Pia
Venuti, Maria Pia
Triggiani, Antonio Ivano
Valenzano, Anna
Resta, Onofrio
Cibelli, Giuseppe
Messina, Giovanni
Physical Activity as a New Tool to Evaluate the Response to Omalizumab and Mepolizumab in Severe Asthmatic Patients: A Pilot Study
title Physical Activity as a New Tool to Evaluate the Response to Omalizumab and Mepolizumab in Severe Asthmatic Patients: A Pilot Study
title_full Physical Activity as a New Tool to Evaluate the Response to Omalizumab and Mepolizumab in Severe Asthmatic Patients: A Pilot Study
title_fullStr Physical Activity as a New Tool to Evaluate the Response to Omalizumab and Mepolizumab in Severe Asthmatic Patients: A Pilot Study
title_full_unstemmed Physical Activity as a New Tool to Evaluate the Response to Omalizumab and Mepolizumab in Severe Asthmatic Patients: A Pilot Study
title_short Physical Activity as a New Tool to Evaluate the Response to Omalizumab and Mepolizumab in Severe Asthmatic Patients: A Pilot Study
title_sort physical activity as a new tool to evaluate the response to omalizumab and mepolizumab in severe asthmatic patients: a pilot study
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6992710/
https://www.ncbi.nlm.nih.gov/pubmed/32038267
http://dx.doi.org/10.3389/fphar.2019.01630
work_keys_str_mv AT carpagnanogiovannaelisiana physicalactivityasanewtooltoevaluatetheresponsetoomalizumabandmepolizumabinsevereasthmaticpatientsapilotstudy
AT sessafrancesco physicalactivityasanewtooltoevaluatetheresponsetoomalizumabandmepolizumabinsevereasthmaticpatientsapilotstudy
AT sciosciagiulia physicalactivityasanewtooltoevaluatetheresponsetoomalizumabandmepolizumabinsevereasthmaticpatientsapilotstudy
AT lacedoniadonato physicalactivityasanewtooltoevaluatetheresponsetoomalizumabandmepolizumabinsevereasthmaticpatientsapilotstudy
AT foschinomariapia physicalactivityasanewtooltoevaluatetheresponsetoomalizumabandmepolizumabinsevereasthmaticpatientsapilotstudy
AT venutimariapia physicalactivityasanewtooltoevaluatetheresponsetoomalizumabandmepolizumabinsevereasthmaticpatientsapilotstudy
AT triggianiantonioivano physicalactivityasanewtooltoevaluatetheresponsetoomalizumabandmepolizumabinsevereasthmaticpatientsapilotstudy
AT valenzanoanna physicalactivityasanewtooltoevaluatetheresponsetoomalizumabandmepolizumabinsevereasthmaticpatientsapilotstudy
AT restaonofrio physicalactivityasanewtooltoevaluatetheresponsetoomalizumabandmepolizumabinsevereasthmaticpatientsapilotstudy
AT cibelligiuseppe physicalactivityasanewtooltoevaluatetheresponsetoomalizumabandmepolizumabinsevereasthmaticpatientsapilotstudy
AT messinagiovanni physicalactivityasanewtooltoevaluatetheresponsetoomalizumabandmepolizumabinsevereasthmaticpatientsapilotstudy